Sat.Oct 09, 2021 - Fri.Oct 15, 2021

article thumbnail

CRISPR touts new results as fresh questions surround 'off-the-shelf' CAR-T

Bio Pharma Dive

The gene editing company aims to expand its trial and add a second dose to improve effectiveness. However, safety worries have emerged since the FDA ordered CRISPR's rival Allogene to suspend clinical work.

article thumbnail

Pharmapack Europe 2021 Award Winners Announced

Pharma Mirror

Paris, Pharmapack Europe (#PharmapackEU) announce the winners of the 2021 Pharmapack Awards and, due to the exceptional quality of this year’s entries, seven winners have been chosen across both the ‘Exhibitor Innovation’ and ‘Health Product’ awards. The Exhibitor Innovation awards recognise four winners plus one highly commended product. EVEON was given the ‘routes of administration’ innovation award for their Intuity® Spray.

Packaging 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DTC is evolving: 10 things you must do

World of DTC Marketing

SUMMARY : DTC marketing is evolving as patients become more thoughtful about choosing treatment options. The model of “heavy TV followed by a website designed to sell people isn’t going to work anymore. I hear more and more from top pharma clients that “our DTC ROI is not where we want it to be.” In a detailed analysis across different health conditions, I’m finding two common causes.

article thumbnail

In the News: September 2021 Regulatory and Development Updates

Camargo

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. FDA Discusses Focus Areas for PDUFA VII During Public Meeting. Following the August publication of the proposed PDUFA VII commitment letter negotiated with industry, the FDA held its corresponding required public meeting on September 28.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Sarepta outlines final push for Duchenne gene therapy

Bio Pharma Dive

The biotech still believes a speedy approval filing for the closely watched treatment is possible, but expects to have to wait for the results of the recently launched Phase 3 trial, CEO Doug Ingram said on a conference call.

article thumbnail

Moderna, Racing for Profits, Keeps Covid Vaccine Out of Reach of Poor

NY Times

Some poorer countries are paying more and waiting longer for the company’s vaccine than the wealthy — if they have access at all.

Vaccine 145

More Trending

article thumbnail

Samsung Biologics to help Enzolytics advance clinical development of mAbs

BioPharma Reporter

Samsung Biologics and Enzolytics have entered into a strategic CDMO partnership agreement targeting monoclonal antibody production.

article thumbnail

Adamas, Flexion sell for $825M combined as biotech's dealmaking pace picks up

Bio Pharma Dive

After lagging for months, M&A has accelerated over the past five weeks. But the average size of each transaction remains low compared to past years, as evidenced by the dual Monday buyouts of Adamas and Flexion.

338
338
article thumbnail

Sanofi’s BTK inhibitor tolebrutinib shows ‘promising’ long-term MS data

Pharma Times

Tolebrutinib reduced multiple sclerosis (MS) disease activity as measured by MRI

135
135
article thumbnail

Topelia Australia launches US$25M Series A call for COVID-19 ATT Ziverdox

Pharma Mirror

SYDNEY,Topelia Australia, a biotech company established to commercialise a novel ATT treatment for Australians in quarantine, has launched an investment program designed to keep the invention Australian owned – while rolling out treatment to the world. – Topelia announces US$25 mil Series A capital raise to fund manufacture and clinical trials of the COVID-19 Antiviral Triple Therapy (ATT).– Topelia has secured exclusive global patent rights to COVID-19 Antiviral Triple Therapy

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Healthware Group appoints Eugene Borukhovich as senior advisor

pharmaphorum

Digital Health veteran Eugene Borukhovich has joined Healthware Group as senior advisor to its Media and Community business unit, which aims to foster dialogue and connections among the digital health community. He is a serial intra- and entrepreneur, angel investor and venture builder and is currently scaling YourCoach Health as its co-founder and COO.

Pharmacy 124
article thumbnail

FDA advisers unanimously back Moderna booster shot for many Americans

Bio Pharma Dive

But the committee members remain opposed to broad use of boosters in healthy young adults, for whom the benefits of an additional shot are less clear.

336
336
article thumbnail

Innovate UK funded NA-ATTC adds three new industry partners

Pharma Times

The ATTC is coordinated as part of the Cell and Gene Therapy Catapult, and operates within the NHS framework

article thumbnail

Romaco at CIPM 2021 in Chengdu, China

Pharma Mirror

The right solution for every process step Karlsruhe/Germany, Romaco will take advantage of the upcoming CIPM 2021 (61st China International Pharmaceutical Machinery Exposition) to show its newest technologies for manufacturing and packing oral solids. From granulation, tableting and coating to packing into blisters and cartons, Romaco has the right solution for every process step.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

No return to the status quo: Why now is the time for value-based change

pharmaphorum

Value-based, person-centred healthcare is the key to system resilience – and now is the time to make it happen. COVID-19 offers a “unique opportunity” to build healthcare systems that are both agile enough to deal with future crises and strong enough to overcome existing challenges. That’s according to a new policy paper from the European Alliance for Value in Health.

Medicine 119
article thumbnail

Takeda takes aim at a biotech's gene therapy work

Bio Pharma Dive

For an upfront payment of $45 million, Takeda gains access to as many as eight programs from Poseida Therapeutics and a potential method of delivering gene therapies without the help of viruses.

article thumbnail

UK pharmacy M&A transactions up by 26%

Pharma Times

Pharmacies saw increased customer demand during the pandemic, says UHY Hacker Young

Pharmacy 114
article thumbnail

InSilicoTrials releases two new state-of-the-art simulation tools for oncology 

Pharma Mirror

Milan, InSilicoTrials has been innovating the healthcare sector for some years now, helping pharmaceutical companies reduce the time and cost of drug development using modeling & simulation. The release of two new products for oncology that have no equals on the market – PCa GnRH Agonists Simulator and CTx NeutroSim – is going to accelerate the growth of this startup with offices in Italy, USA and the Netherlands.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Headspace and Ginger finalise $3bn digital mental health merger

pharmaphorum

Headspace and Ginger have completed their $3 billion combination to create Headspace Health, a new frontrunner in the rapidly growing digital mental health and wellbeing sectors. The company will be led by Ginger’s former CEO Russell Glass, while Headspace’s co-founders Andy Puddicombe and Richard Pierson will sit alongside him on Headspace Health’s new board of directors.

article thumbnail

FDA panel endorses second shot for adults who received J&J vaccine

Bio Pharma Dive

Agency advisers unanimously supported offering a second dose of J&J's coronavirus vaccine to adults who previously received it, though guidance could change as regulators evaluate mixing boosters.

Vaccine 331
article thumbnail

Phase III trial shows AZ’s liver cancer combination improves overall survival

Pharma Times

Patients in the trial were those with unresectable hepatocellular carcinoma (HCC) who had not received systemic therapy treatment previously, and were not eligible for localised treatment

Trials 111
article thumbnail

Why Kids Need Positive Role Models

Pharma Mirror

The importance of teaching children and teens about healthy relationships is becoming more and more apparent. This education starts with teaching them the importance of their self-worth as well as that of others. Kids need to see healthy relationships modeled to understand what they should be striving for in their own life’s relationships. Role models are an essential part of this process.

130
130
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Data dive finds cheap diuretic could be Alzheimer’s drug

pharmaphorum

A data-mining study conducted by researchers in the US has found that an already-approved diuretic drug could have potential as a treatment for some patients with Alzheimer’s disease. The research by a team of National Institutes of Health (NIH) scientists found that people who took bumetanide, a generic drug usually used to treat heart failure and oedema, had a significantly lower prevalence of Alzheimer’s compared to those not taking the drug.

article thumbnail

Merck advantage grows as FDA approves Keytruda for first-line cervical cancer

Bio Pharma Dive

The company's immunotherapy is the only drug of its type cleared for advanced cervical cancer. Others are being tested, however.

article thumbnail

Association Between Risk of COVID-19 in Nonimmune Individuals and Immunity in Family Members

JAMA Internal Medicine

This cohort study examines the spread of COVID-19 infection within family members living in the same residence with different levels of immunity.

111
111
article thumbnail

Alzheimer’s Drug Granted FDA Breakthrough Designation as Space Heats Up

BioSpace

?The decision is based on promising results from the Marguerite RoAD and SCarlet RoAD open-label extension trials, showing a significant reduction in brain amyloid plaque in Alzheimer's patients.

Drugs 108
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

WHO plans pandemic prevention study of COVID’s origins

pharmaphorum

The World Health Organization has set up a new scientific group to study the origins of COVID-19 in the hope that it will help prevent future pandemics. The new Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) will bring together experts from areas such as epidemiology, animal health, clinical medicine, virology and genomics. WHO chief Tedros Adhanom Ghebreyesus said: “SAGO will advise WHO on the development of a global framework to define and guide studies into the origins of

Genomics 109
article thumbnail

NIH study finds mixing COVID-19 boosters increases immune response

Bio Pharma Dive

Results suggested Pfizer's and Moderna's vaccines may serve as a more potent booster for those who initially received Johnson & Johnson's shot, although data are limited and preliminary.

article thumbnail

MHRA backs Merck’s MET inhibitor Tepmetko

Pharma Times

Conditional marketing authorisation granted for patients with advanced NSCLC with METex14 skipping alterations

Marketing 107
article thumbnail

WHO Honors the Legacy and Contribution of Henrietta Lacks

XTalks

The World Health Organization (WHO) honored the late Henrietta Lacks with a posthumous award to recognize her life, legacy and contribution to science as a Black woman whose cells became the first “immortal” cell line, leading them to become one of the most important and widely used in scientific research. The WHO’s Director-General Dr. Tedros Adhanom Ghebreyesus honored Henrietta Lacks with a WHO Director-General’s award, “recognizing the world-changing legacy of this Black American woman who d

Vaccine 105
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.